Billiontoone (NASDAQ:BLLN) Stock: Insider David Tsao Sells 20,000 Shares

Billiontoone, Inc. (NASDAQ:BLLN) CTO David Tsao sold 20,000 shares of the stock in a transaction dated Monday, November 2nd. The shares were sold at an average price of $109.24, for a total value of $2,184,800.00. Following the completion of the sale, the chief technology officer owned 1,000 shares of the company’s stock, valued at approximately $109,240. This trade represents a 95.24% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

David Tsao also recently made the following trade(s):

• On Monday, October 5th, David Tsao sold 20,000 shares of Billiontoone stock. The stock was sold at an average price of $108.15, for a total value of $2,163,000.00.
• On Thursday, September 24th, David Tsao sold 3,333 shares of Billiontoone stock. The stock was sold at an average price of $125.00, for a total value of $416,625.00.
• On Wednesday, September 9th, David Tsao sold 20,000 shares of Billiontoone stock. The shares were sold at an average price of $98.77, for a total transaction of $1,975,400.00.
• On Tuesday, August 25th, David Tsao sold 10,000 shares of Billiontoone stock. The shares were sold at an average price of $100.00, for a total transaction of $1,000,000.00.
• On Monday, August 10th, David Tsao sold 10,000 shares of Billiontoone stock. The shares were sold at an average price of $92.86, for a total transaction of $928,600.00.

Billiontoone Stock Up 3.1%

Shares of NASDAQ BLLN traded up $3.44 during trading on Wednesday, reaching $113.89. 582,091 shares of the stock were exchanged, compared to its average volume of 469,134. The company has a market capitalization of $5.37 billion and a price-to-earnings ratio of 157.79. The business’s 50-day moving average price is $104.67 and its 200 day moving average price is $96.89. The company has a quick ratio of 11.31, a current ratio of 11.69 and a debt-to-equity ratio of 0.17. Billiontoone, Inc. has a twelve month low of $61.96 and a twelve month high of $150.44.

Billiontoone (NASDAQ:BLLN) last released its quarterly earnings results on Wednesday, August 5th. The company reported $0.15 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.15. Billiontoone had a net margin of 8.04% and a return on equity of 9.96%. The firm had revenue of $109.45 million for the quarter. As a group, equities analysts forecast that Billiontoone, Inc. will post 0.80 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the company. Parallel Advisors LLC increased its holdings in shares of Billiontoone by 86.7% in the 3rd quarter. Parallel Advisors LLC now owns 280 shares of the company’s stock valued at $30,000 after acquiring an additional 130 shares during the last quarter. Integrated Wealth Concepts LLC acquired a new stake in shares of Billiontoone during the 2nd quarter valued at approximately $29,000. Toth Financial Advisory Corp raised its position in shares of Billiontoone by 60.0% during the 3rd quarter. Toth Financial Advisory Corp now owns 800 shares of the company’s stock valued at $85,000 after acquiring an additional 300 shares in the last quarter. MCF Advisors LLC raised its position in shares of Billiontoone by 330.8% during the 2nd quarter. MCF Advisors LLC now owns 448 shares of the company’s stock valued at $54,000 after acquiring an additional 344 shares in the last quarter. Finally, Family Legacy Financial Solutions LLC bought a new position in Billiontoone during the third quarter worth $53,000.

Wall Street Analysts Forecast Growth

BLLN has been the subject of a number of recent analyst reports. BTIG Research lowered their price objective on Billiontoone from $142.00 to $130.00 and set a “buy” rating for the company in a research note on Thursday, August 6th. JPMorgan Chase & Co. cut their target price on Billiontoone from $145.00 to $130.00 and set an “overweight” rating on the stock in a research report on Thursday, August 6th. Guggenheim increased their target price on Billiontoone from $125.00 to $128.00 and gave the company a “buy” rating in a research note on Thursday, October 1st. Weiss Ratings downgraded shares of Billiontoone from a “sell (d+)” rating to a “sell (d)” rating in a research report on Thursday, October 8th. Finally, Zacks Research raised shares of Billiontoone from a “strong sell” rating to a “hold” rating in a research report on Friday, October 2nd. Seven equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $126.25.

Trending Headlines about Billiontoone

Here are the key news stories impacting Billiontoone this week:

• Positive Sentiment: Q3 results topped expectations: Revenue was about $123.0 million, above the $115.8 million FactSet estimate. Reported earnings per share also exceeded the $0.16 consensus, although sources cite different actual EPS figures ($0.32 and $0.48). BillionToOne Q3 results and guidance
• Positive Sentiment: Higher 2026 revenue guidance: The company raised its full-year revenue outlook, signaling improved expectations for growth. Company announcement
• Negative Sentiment: Multiple insiders sold shares: The CEO, CTO and an SVP reported sales. The transactions were made under pre-arranged Rule 10b5-1 plans, which may temper—but do not eliminate—the bearish signal investors could take from insider selling. Insider transaction reports

About Billiontoone

BillionToOne, Inc is a molecular diagnostics company that develops tests designed to provide more sensitive and quantitative genetic information from blood samples. The company’s technology is based on its proprietary Quantitative Counting Template (QCT) platform, which is designed to measure DNA molecules with high sensitivity and support the detection of clinically meaningful genetic signals.

The company’s products include prenatal diagnostic and screening solutions marketed under the UNITY brand.